The 80th Annual Meeting of the Japanese Society of Hematology

Session information

Print

Oral Session

Oral Session 2-9B CML: Clinical trials

Sat. Oct 13, 2018 10:10 AM - 11:10 AM No.9 (Osaka International Convention Center, 10F 1008)

Chair: Chikashi Yoshida (Department of Hematology, National Hospital Oganization Mito Medical Center, Japan)

【Ｅ】

[OS2-9B-1] Long term efficacy of TKI therapy for chronic myeloid leukemia; a single center experience

Emiko Sakaida1, Jun Takiguchi1, Chikako Ohwada1, Takaaki Tanami1, Yasuhito Hatanaka1, Arata Ishii1, Miki Yamazaki1, Yurie Nagai1, Tatsuzo Mishina1, Yutaro Hino1, Koji Takaishi1, Yusuke Isshiki1, Kenji Kimura1, Kensuke Kayamori1, Nagisa Oshima1, Shokichi Tsukamoto1, Shio Mitsukawa1,2, Yusuke Takeda1, Naoya Mimura1,2, Masahiro Takeuchi1, Tohru Iseki1,2, Chiaki Nakaseko1,3 (1.Department of Hematology, Chiba University Hospital, 2.Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3.Department of Hematology, International University of Health and Welfare, Narita)

[OS2-9B-2] Impact of tyrosine kinase inhibitor on adult height in chronic-phase CML children

Haruko Shima1, Akihiko Tanizawa1, Hidemitsu Kurosawa1, Akihiro Watanabe1, Masaki Ito1, Chikako Tono1, Yuki Yuza1, Hideki Muramatsu1, Kazuko Hamamoto1, Masahiko Okada1, Koji Kato2, Kimikazu Matsumoto3, Norio Shiba4, Hiroyuki Shimada1 (1.JCCG, CML committee, 2.Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Aichi, Japan, 3.Children's Cancer Center, NCCHD, Tokyo, Japan, 4.Dept. Pediatrics, Yokohama City University Hospital, Kanagawa, Japan)

[OS2-9B-3] Analysis of cardiovascular risk factors in nilotinib-treated Japanese CML patients

Isao Fujioka1, Tomoiku Takaku1, Michihide Tokuhira2, Yuta Kimura2, Eisaku Iwanaga3, Keiji Sugimoto4, Tomonori Nakazato5, Noriyoshi Iriyama6, Eriko Sato7, Maho Ishikawa8, Hiroyuki Fujita9, Norio Asou8, Yoshihiro Hatta6, Masahiro Kizaki2, Norio Komatsu1, Tatsuya Kawaguchi10 (1.Dept. Hematology, Juntendo University School of Medicine, Tokyo, Japan, 2.Dept. Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 3.Dept. Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan, 4.Dept. Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan, 5.Dept. Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, 6.Div. Hematology & Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 7.Div. Hematology, Dept. Medicine, Juntendo University Nerima Hospital, Tokyo,, 8.Hemato-Oncology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, 9.Dept. Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan, 10.Kumamoto Health Science University, Kumamoto, Japan)

[OS2-9B-4] Additional chromosomal abnormalities at diagnosis and their impact on treatment response in CML

Maho Ishikawa1, Noriyoshi Iriyama2, Michihide Tokuhira3, Tomoiku Takaku4, Eriko Sato5, Keiji Sugimoto6, Tomonori Nakazato7, Eisaku Iwanaga8, Hiroyuki Fujita9, Yuta Kimura3, Isao Fujioka4, Norio Komatsu4, Norio Asou1, Masahiro Kizaki3, Yoshihiro Hatta2, Tatsuya Kawaguchi10 (1.Dept. Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan., 2.Division of Hematology and Rheumatology, Nihon University, Tokyo, Japan, 3.Dept. Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan, 5.Division of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan, 6.Department of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan, 7.Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, 8.Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan, 9.Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan, 10.Kumamoto Health Science University, Kumamoto, Japan)

[OS2-9B-5] Interim results of a post-marketing surveillance of ponatinib

Kiyohiko Hatake1,2,3,4,5, Takahiro Yoshida2, Moriyoshi Yasuda3, Mihoko Ota3, Akira Masunari3, Yasuhiko Fukuta3, Yuji Ikari4, Arinobu Tojo5 (1.Hematology, International University of Health and Welfare,Tokyo, Japan, 2.Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 3.Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 4.Tokai University School of Medicine, Kanagawa, Japan, 5.The Institute of Medical Science, The University of Tokyo, Japan)

[OS2-9B-6] Efficacy and safety of first-line bosutinib vs imatinib in Asian patients in the BFORE trial

Charles Chuah1, Liang Piu Koh2, Tontanai Numbenjapon3, Dae Young Zang4, Kiat Hoe Ong5, Young Rok Do6, Eric Leip7, Chiho Ono8, Rocco Crescenzo9, Jorge Cortes10, Tim Brümmendorf11, Carlo Gambacorti-Passerini12, Michael Deininger13, Michael Mauro14, Andreas Hochhaus15, Dong-Wook Kim16 (1.Singapore General Hospital, Duke-NUS Medical School, Singapore, Republic of Singapore, 2.National University Cancer Institute, Singapore, Republic of Singapore, 3.Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Kingdom of Thailand, 4.Hallym University Sacred Heart Hospital, Anyang, Republic of Korea, 5.Tan Tock Seng Hospital, Singapore, Republic of Singapore, 6.Keimyung University, Daegu, Republic of Korea, 7.Pfizer Inc, Cambridge, United States of America, 8.Pfizer Japan Inc, Tokyo, Japan, 9.Pfizer Inc, Collegeville, United States of America, 10.University of Texas MD Anderson Cancer Center, Houston, United States of America, 11.Universitätsklinikum RWTH Aachen, Aachen, Federal Republic of Germany, 12.University of Milano-Bicocca, San Gerardo Hospital, Monza, Italian Republic, 13.University of Utah, Salt Lake City, United States of America, 14.Memorial Sloan Kettering Cancer Center, New York, United States of America, 15.Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Federal Republic of Germany, 16.Seoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Republic of Korea)